Syracuse

Immunotherapy for LELC: Case Report and a Focused Review

Archive ouverte

Darrason, Marie | Martin, Antoine | Soussan, Michael | Chouahnia, Kader | Pailler, Marie-Christine | Boudabous, Hanene | Brillet, Pierre-Yves | Bousquet, Guilhem | Zelek, Laurent | Duchemann, Boris

Edité par CCSD ; Elsevier -

International audience. Lymphoepithelioma-like carcinoma of the lung (LELC) is a rare, Epstein-Barr virus-associated tumor. LELC occurs mostly in young, Asian nonsmokers. A few hundred cases have been reported, mostly from retrospective Asian studies. Optimal treatment has not been clearly established. Treatment options are based on surgery for early stage and on cisplatin-based chemotherapy as first-line therapy for metastatic disease. Prognosis may seem better than for other types of nonesmall-cell lung cancer, but it remains poor in advanced disease, with a median survival of 24 months, and new treatments options are still warranted. Immunotherapies are now key players in the treatment of non esmall-cell lung cancer. However, few data are available for this rare histologic subgroup. We have reviewed the available data on LELC with a focus on the first few cases reported with a response to a programmed cell death 1 inhibitor.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion